Jump to content

Prazitone

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 20:13, 2 April 2016 (Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Prazitone
Clinical data
Other names5-phenyl-5-(2-piperidylmethyl)barbituric acid
ATC code
  • none
Identifiers
  • 5-phenyl-5-(piperidin-2-ylmethyl)pyrimidine-2,4,6(1H,3H,5H)-trione
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H19N3O3
Molar mass301.34 g/mol g·mol−1
3D model (JSmol)
  • C1CCNC(C1)CC2(C(=O)NC(=O)NC2=O)C3=CC=CC=C3
  • InChI=1S/C16H19N3O3/c20-13-16(11-6-2-1-3-7-11,14(21)19-15(22)18-13)10-12-8-4-5-9-17-12/h1-3,6-7,12,17H,4-5,8-10H2,(H2,18,19,20,21,22) ☒N
  • Key:UGZAKKMLMJITLL-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Prazitone (AGN-511) is a barbiturate derivative developed in the 1970s.[1] Unlike most barbiturates, it has little or no sedative effects, instead acting as a non-sedating anxiolytic and antidepressant.[2] The dosage range in humans is around 200–600 mg, although higher doses have been used in trials for the treatment of depression associated with Parkinson's disease.

References